SBI Securities Co. Ltd. Acquires New Holdings in IQVIA Holdings Inc. (NYSE:IQV)

SBI Securities Co. Ltd. bought a new position in IQVIA Holdings Inc. (NYSE:IQV) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 307 shares of the medical research company’s stock, valued at approximately $60,000.

Several other large investors have also recently bought and sold shares of the company. Farther Finance Advisors LLC increased its holdings in shares of IQVIA by 35.2% in the 3rd quarter. Farther Finance Advisors LLC now owns 407 shares of the medical research company’s stock worth $96,000 after buying an additional 106 shares during the last quarter. Impax Asset Management Group plc increased its stake in IQVIA by 9.7% in the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock valued at $423,885,000 after acquiring an additional 157,809 shares during the last quarter. Principal Financial Group Inc. raised its position in IQVIA by 0.8% during the third quarter. Principal Financial Group Inc. now owns 209,021 shares of the medical research company’s stock valued at $49,532,000 after purchasing an additional 1,750 shares in the last quarter. Capital Performance Advisors LLP bought a new stake in IQVIA during the third quarter worth about $27,000. Finally, Assetmark Inc. boosted its holdings in shares of IQVIA by 612.5% in the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after purchasing an additional 196 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. Bank of America decreased their target price on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a report on Friday, December 13th. Morgan Stanley raised their price target on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Truist Financial reaffirmed a “buy” rating and issued a $263.00 price objective (up from $261.00) on shares of IQVIA in a research report on Monday, February 10th. Finally, StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Price Performance

NYSE IQV opened at $188.72 on Tuesday. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The business’s fifty day moving average is $197.62 and its 200 day moving average is $212.24. The company has a market capitalization of $33.27 billion, a PE ratio of 25.16, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a fifty-two week low of $179.28 and a fifty-two week high of $261.72.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.